Multicell Technologies (MCET) Stock Price
Multicell Technologies Price
Over the last 19 years Multicell Technologies grew revenue by 8.8% annually, reaching 49,300.00 USD. For Multicell Technologies, the net margin of -771.0% is up versus -1,314.0% a few years ago.
Multicell Technologies stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Multicell Technologies over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Multicell Technologies stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Multicell Technologies's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Multicell Technologies Price |
|---|---|
| 9/2/2026 | 0.00 USD |
| 9/1/2026 | 0.00 USD |
| 8/31/2026 | 0.00 USD |
| 8/28/2026 | 0.00 USD |
| 8/27/2026 | 0.00 USD |
| 8/26/2026 | 0.00 USD |
| 8/25/2026 | 0.00 USD |
| 8/24/2026 | 0.00 USD |
| 8/21/2026 | 0.00 USD |
| 8/20/2026 | 0.00 USD |
| 8/19/2026 | 0.00 USD |
| 8/18/2026 | 0.00 USD |
| 8/17/2026 | 0.00 USD |
| 8/14/2026 | 0.00 USD |
| 8/13/2026 | 0.00 USD |
| 8/12/2026 | 0.00 USD |
| 8/11/2026 | 0.00 USD |
| 8/10/2026 | 0.00 USD |
| 8/7/2026 | 0.00 USD |
| 8/6/2026 | 0.00 USD |
| 8/5/2026 | 0.00 USD |
| 8/4/2026 | 0.00 USD |
| 8/3/2026 | 0.00 USD |
| 7/30/2026 | 0.00 USD |
| 7/29/2026 | 0.00 USD |
| 7/28/2026 | 0.00 USD |
| 7/27/2026 | 0.00 USD |
| 7/24/2026 | 0.00 USD |
| 7/23/2026 | 0.00 USD |
| 7/22/2026 | 0.00 USD |
Multicell Technologies Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Multicell Technologies Income Statement, Balance Sheet, Cash Flow Statement
| EBITM USD |
|---|
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESB |
| 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | -1.00 | -1.00 | -1.00 | -1.00 | -4.00 | -5.00 | -3.00 | -1.00 | – | -1.00 | -2.00 | -1.00 | -1.00 | – |
| – | – | -1.00 | -1.00 | -1.00 | -3.00 | -5.00 | -7.00 | -3.00 | -2.00 | – | -1.00 | -1.00 | -1.00 | -1.00 | – |
| – | – | – | – | – | 200.00 | 66.67 | 40.00 | -57.14 | -33.33 | – | – | – | – | – | – |
| 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0.04 | 0.04 | 0.06 | 0.19 | 0.38 | 0.69 | 1.04 | 1.92 | 3.73 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Multicell Technologies generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Multicell Technologies retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Multicell Technologies's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Multicell Technologies has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Multicell Technologies's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Multicell Technologies stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Multicell Technologies Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Multicell Technologies business model & stock analysis
Multicell Technologies SWOT Analysis
Strengths
Multicell Technologies Inc is known for its advanced research and development capabilities, which allow the company to innovate and develop cutting-edge technologies in the field of cell biology.
The company has a strong intellectual property portfolio, including patents and trademarks, giving it a competitive advantage and providing barriers to entry for potential competitors.
Multicell Technologies Inc has established strategic partnerships with key industry players, enabling access to additional resources and expertise in various areas of the business.
Weaknesses
The company relies heavily on external funding to support its research and development activities, which exposes it to risks associated with changes in funding availability or investor sentiment.
Multicell Technologies Inc faces challenges in scaling up its production processes to meet increasing market demand, which may result in delays or production inefficiencies.
The company's current product portfolio is limited and highly focused, making it vulnerable to shifts in market trends or technological advancements that could render their products obsolete.
Opportunities
The growing demand for cell-based therapies and regenerative medicine presents significant opportunities for Multicell Technologies Inc to expand its product offerings and enter new markets.
Advancements in technology and increasing public awareness of the potential of cell-based treatments provide a favorable market environment for the company to gain a competitive advantage.
Multicell Technologies Inc can leverage its research capabilities to develop strategic partnerships with pharmaceutical companies, opening up opportunities for collaboration and co-developing products for specific applications.
Threats
The regulatory landscape for cell-based therapies is complex and subject to change, posing potential challenges and delays in obtaining necessary approvals for commercialization.
Competition in the cell biology industry is intensifying, with the entry of new players and established companies investing heavily in research and development. This competitive pressure may erode Multicell Technologies Inc's market share.
Economic downturns or financial instability in the healthcare sector could impact customer spending and reduce demand for the company's products.
Multicell Technologies Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Multicell Technologies historical P/E ratio, EBIT multiple, and P/S ratio
Multicell Technologies annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Multicell Technologies shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Multicell Technologies stock splits
Multicell Technologies Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 10/17/2005 | -0.04USD | - | 55,824.00USD | - | 2005 Q3 |
Multicell Technologies Executives and Management Board
5 members · avg. age 73 · 0 % women
Mr. W. Gerald Newmin (82)
Chairman of the Board, President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary · since 1995
185,720.00 USD
Dr. Stephen Chang
Director · since 2004
Mr. Grant Miller (64)
Director
Mr. Thomas Page (86)
Independent Director
Mr. Edward Sigmond (61)
Independent Director
Frequently asked questions about Multicell Technologies
The business model of Multicell Technologies Inc revolves around the development and commercialization of innovative therapeutic products for the treatment of neurological disorders, including Multiple Sclerosis (MS), traumatic brain injury (TBI), and spinal cord injury (SCI). The company focuses on utilizing its proprietary platform technology, known as the "MCT-5000," which allows for the creation of specialized cells to facilitate tissue regeneration and repair. Through partnerships and collaborations, Multicell aims to translate its scientific advancements into novel therapeutics that can address unmet medical needs and improve the quality of life for patients.
Multicell Technologies Inc is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of Multicell Technologies Inc in the market include other companies in the biotechnology and pharmaceutical industries, particularly those focused on researching and developing innovative therapeutics. Some notable competitors in this space include companies like Amgen, Inc., Gilead Sciences, Inc., Biogen Inc., and Novartis AG. These companies also operate within the healthcare sector and compete in areas such as drug development, clinical trials, market share, and breakthrough therapies.
Multicell Technologies Inc. is a company with a rich history and background. Founded in [insert year], Multicell Technologies has established itself as a leading player in the [insert industry] sector. With a focus on innovation and technological advancements, the company has consistently strived to deliver cutting-edge solutions to its customers. Multicell Technologies Inc. has achieved significant milestones, carving a niche for itself in the market. The company's commitment to quality, customer satisfaction, and continuous growth has propelled its success and garnered a strong reputation in the industry. Multicell Technologies Inc. continues to expand its horizons, aiming to redefine excellence and lead the way in its field.
Multicell Technologies Inc has achieved several significant milestones since its inception. The company has successfully developed innovative biopharmaceutical technologies that have garnered recognition within the industry. Multicell Technologies Inc has also obtained various patents for its groundbreaking discoveries, further solidifying its position as a leading player in the market. With a strong emphasis on research and development, the company has made significant strides in advancing regenerative medicine and cellular therapies. Multicell Technologies Inc's commitment to innovation and breakthrough solutions has enabled it to establish a prominent presence in the field, driving growth and contributing to its success.
Multicell Technologies Inc is primarily present and operates in multiple countries and regions across the globe. With a global footprint, the company has a strong presence in North America, including the United States and Canada. Additionally, Multicell Technologies Inc has established its operations in Europe, covering countries like Germany, France, and the United Kingdom. The company has also expanded its business reach in Asia, specifically in countries such as China, India, and Japan. Being a globally oriented organization, Multicell Technologies Inc aims to leverage its diverse presence to cater to a wide range of markets and serve its clients effectively.
Multicell Technologies Inc represents values of innovation, collaboration, and customer-centricity. With a strong corporate philosophy focused on pushing the boundaries of technology, Multicell strives to develop cutting-edge solutions for a variety of industries. By constantly staying ahead of industry trends, Multicell ensures that it provides the latest and most efficient products to its customers. Recognized for its commitment to quality and excellence, Multicell Technologies Inc is dedicated to delivering exceptional value and customer satisfaction.
Converted at the current exchange rate, the Multicell Technologies share trades at 0.00 EUR (0.00 USD).
Multicell Technologies Inc. is a company specialized in the development and marketing of products in the field of regenerative medicine. The company's business model is based on providing innovative solutions for the treatment of chronic diseases such as diabetes, arthritis, and cancer using human stem cells. The company offers several divisions, including: 1. Therapeutic products: Multicell Technologies has developed a range of therapeutic products made from human stem cells. These products can be used to treat various chronic diseases. For example, Multistem is a therapeutic cell product platform that aims to help manage stem cells in severe diseases such as multiple sclerosis and heart attack. 2. Research products: The company offers a variety of research products, including cell culture systems and molecular diagnostics. These products support research in the fields of regenerative medicine and stem cell therapy. 3. Services: Multicell also provides services such as conducting clinical studies and consulting services for companies operating in the areas of regenerative medicine and stem cell therapy. The company collaborates with leading academic institutions and research facilities to offer its services. Multicell is a pioneer in the production of human stem cell products that help improve the health and quality of life of patients worldwide. The company's products and services are utilized by a variety of customers in the pharmaceutical and biotech industries, as well as in academic research. The company has a strong presence in the USA and aims to expand its products and services to the global market. Multicell is committed to offering innovative solutions in regenerative medicine to contribute to the cure of diseases. Multicell relies on close collaboration with its customers to understand their needs and requirements and offer innovative solutions that can improve the health and well-being of the population worldwide. In conclusion, Multicell Technologies Inc. is an emerging company in the field of regenerative medicine, specializing in the development and marketing of products and services with the aim of treating chronic diseases and contributing to the improvement of global health and quality of life.
The revenue cannot currently be calculated for Multicell Technologies.
The profit cannot currently be calculated for Multicell Technologies.
The P/E ratio cannot be calculated for Multicell Technologies at the moment.
The P/S cannot be calculated for Multicell Technologies currently.
The Eulerpool Quality Score for Multicell Technologies is 2/10.
The ISIN of Multicell Technologies is US62544S2005. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Multicell Technologies is A0ET6A. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Multicell Technologies is MCET. The ticker symbol is used to trade Multicell Technologies shares on the stock exchange.
Multicell Technologies paid dividends every year for the past 0 years.
Multicell Technologies is assigned to the 'Health' sector.
The dividends of Multicell Technologies are distributed in USD.
Multicell Technologies stock
Multicell Technologies Peer Group
Multicell Technologies FIGI
All fundamentals and in-depth analysis of Multicell Technologies
Our stock analysis for Multicell Technologies stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Multicell Technologies. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.